TEDAVI

Digital

Partner Content

EVERSANA, a leading provider of global commercial services to the life sciences industry, today introduced <

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.